pembrolizumab
merck
['pembro', 'sclc', 'kn789', 'lcsm,(-blcsm)', 'nsclc']
kn789: no benefit for the addition of pembro to egfr mutant mnsclc post tki 1l. crossover allowed in the placebo group. definitely, io does not seem to be the answer in patients with driver mutations post tki pd. and i lost my snapshots of the presentation #asco23 #lcsm
Husband, Father. Medical Oncologist and Researcher focused in Thoracic Oncology.  Views are my own. Member of @latenightonc - the best podcast in oncology!